8月20日至22日，"中国药店·北京同仁堂科技第二届加味逍遥丸·焕新古方药店演说家"活动在北京举办。 据悉，本届活动以加味逍遥丸为纽带，组织各位选手探访北京同仁堂大栅栏店，通过沉浸式体悟中医药 文化的历史底蕴与时代价值，进一步深化对古方焕新的感悟。期间，在由北京同仁堂科技发展股份有限 公司（以下简称"同仁堂科技"）和中国药店搭建的药店演说家舞台之上，从众多报名者中脱颖而出的60 位药店精英用专业之声传递了古方魅力。 本届入围选手按"同仁堂系内"及"全国连锁系外"进行分组比赛，多维度对选手进行考核，同时，多位业 内专家评委老师坐镇指导，以深厚的专业素养与洞察力，为选手们的表现提供了中肯而专业的点评。 广大选手们以同仁堂历史、文化、理念为切入点，结合多年一线销售经验，在案例分享中解构古方焕新 的实践范式；答辩环节，选手结合多年门店服务经验，就患者病症进行用药推荐与健康指导，以多元化 视角诠释药店人的担当与专业价值。 选手秉承循证用药原则，结合病症信息提供个体化用药建议并阐明循证依据；在答辩环节，选手通过药 学科普、病症解析、关联用药等维度定制个性化用药方案，系统诠释古方焕新的新思路，也让现场的氛 围不断升温。 随 ...

夏日上火长痘、暑天头晕乏力、压力大情绪崩溃、久坐后腰膝酸软……这些职场人习以为常的"小毛 病"，却恰恰是健康发出的预警信号。近日，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技 公司"）以"带薪健康2小时"为主题，携多款明星产品走进"去哪儿"旅行公司，用一场集"精准健康解决 方案+专属福利+趣味互动"于一体的健康关怀活动，将百年中医药智慧融入职场日常，为广大职场人的 健康精准护航。 职场人的健康困扰，都藏在一个个具体场景里：加班后的火锅局总让上火长痘成为常态；工作时犯困严 重影响下午效率；工作压力大时容易影响情绪……而北京同仁堂科技公司带来的多款产品，正是为应对 这些"场景化健康需求"而来——每一款产品都能精准匹配职场人的"小烦恼"： 现场：明星产品直击职场健康痛点 下班后小聚的热辣美食引发了上火问题，有祛火"凉"方京制牛黄解毒片带来清凉；夏日通勤带来的暑天 不适，藿香正气水帮助状态回满；午后犯困的头晕脑胀，仁丹可以快速提升重启工作效率；开会高频输 出后气短乏力，一支生脉饮即可补充元气；面对KPI压力、跨部门沟通摩擦时的烦躁易怒，加味逍遥丸 帮职场人疏肝解郁，从容应对挑战；长期伏案导致的腰膝酸软、精力不 ...

Group 1 - The event "She Health, Beautiful Protection for Her" health market was launched in Shanghai, featuring Beijing Tongrentang as a strategic partner of Meituan's women's health public welfare program [1] - Beijing Tongrentang created an interactive health experience area, attracting many women to participate in activities that combined stamp collection, fun challenges, and health benefits [1][3] - The event included limited-time discounts on Tongrentang products, covering health supplements and health teas, making health benefits easily accessible [1] Group 2 - In addition to fun interactions, Beijing Tongrentang set up a public welfare consultation area with experienced traditional Chinese medicine (TCM) practitioners providing free health consultations and personalized advice [3][4] - The activities focused on common sub-health issues among urban women, such as emotional stress and liver qi stagnation, integrating TCM culture into everyday life in a relatable manner [4] Group 3 - As an important partner in Meituan's women's health public welfare program, Beijing Tongrentang actively practices the "She Health" initiative through health markets, public welfare consultations, and health knowledge dissemination [6] - The company emphasizes that these efforts are not only a practical response to the "Healthy China" strategy but also a continuation of its core philosophy of "benefiting the world through health" [6] - Since its establishment in 1669, the company has adhered to the principle of meticulous craftsmanship and quality, embedding public welfare into its development ethos [6] Group 4 - Beijing Tongrentang integrates social responsibility into its corporate actions, aiming to leverage TCM's unique advantages to contribute to the improvement of public health [8]

Investment Rating - The report indicates a positive outlook for the gynecological menstrual regulation medications industry in China, driven by increasing female health awareness and supportive policies [3]. Core Insights - The gynecological menstrual regulation medications industry in China has shown steady growth, supported by rising demand and policy benefits, with a focus on women's health needs [3]. - The market is expected to expand further due to the emergence of the "she economy" and the aging population, highlighting the potential in menopause management and reproductive health segments [3]. - The industry is characterized by a dual approach of Western and traditional Chinese medicine, with Western medications primarily consisting of hormone-based drugs and Chinese medicine focusing on holistic treatment [4][5]. Summary by Sections Industry Overview - Menstrual disorders are common among women, with significant differences in treatment approaches between Western and Chinese medicine [4]. - The report defines gynecological menstrual regulation medications as those that adjust reproductive endocrine functions or overall physiological functions to restore normal menstrual cycles [35][36]. Market Size - The market for gynecological menstrual regulation medications is projected to reach 238.9 billion yuan in 2024, with a growth forecast to 312.8 billion yuan by 2029 [43]. - The growth is attributed to increased awareness of women's health and rising incidence of gynecological diseases, particularly among younger women [43][44]. Industry Chain Analysis - The upstream analysis indicates that rising raw material prices are increasing production costs, with leading companies showing resilience due to resource advantages [53][54]. - The midstream analysis reveals a stable growth in the market driven by consumer demand, with a concentration of market share among leading brands [57][61]. - The downstream analysis highlights the growth of online channels, providing significant development opportunities for the industry [65]. Competitive Landscape - The competitive landscape shows a mix of established companies and smaller players, with leading firms leveraging brand strength and distribution advantages [61][62]. - The report notes that traditional Chinese medicine products dominate the market, while Western medications are gaining traction due to their targeted treatment capabilities [43][44].

Investment Rating - The report indicates a positive outlook for the gynecological menstrual regulation medications industry in China, driven by increasing awareness of women's health and supportive policies [3]. Core Insights - The gynecological menstrual regulation medications industry in China has shown steady growth, propelled by rising market demand and policy benefits, with a focus on women's health needs [3]. - The market is expected to expand significantly due to the emergence of the "she economy" and the aging population, highlighting the potential in menopause management and reproductive health segments [3]. - The industry is characterized by a dual approach to treatment, with Western medicine focusing on hormonal therapies and traditional Chinese medicine emphasizing holistic care [4][5]. Summary by Sections Industry Overview - Menstrual disorders are common among women, with significant differences in treatment approaches between Western and Chinese medicine [4]. - The report defines gynecological menstrual regulation medications as drugs that restore normal menstrual cycles through endocrine regulation [35]. Market Size - The market for gynecological menstrual regulation medications is projected to reach 238.9 billion yuan in 2024, with a growth forecast to 312.8 billion yuan by 2029 [43]. - The market growth is attributed to increased demand for gynecological disease management and supportive policies, with a notable rise in awareness of women's health [41][43]. Industry Chain Analysis - The upstream analysis indicates that rising raw material prices are increasing production costs, impacting smaller companies more than larger ones [53][54]. - The midstream analysis shows a stable growth in the market driven by consumer demand, with a concentration of market share among leading companies [57][61]. - The downstream analysis highlights the growth of online sales channels, providing significant opportunities for the industry [65]. Competitive Landscape - The competitive landscape is marked by a mix of established brands and smaller players, with leading companies leveraging brand strength and distribution advantages [61][62]. - The report notes that traditional Chinese medicine products dominate the market, benefiting from their natural attributes and policy support [43][44].

Group 1 - The "She Health - Meituan Women's Health Public Welfare Program" was officially launched in Shanghai, focusing on creating a health management system for over 30 working women through a collaboration between government, enterprises, and medical institutions [1][3] - Beijing Tongrentang, a representative brand of traditional Chinese medicine, emphasizes the importance of liver health for women and integrates the concept of "preventive treatment" into health management, addressing modern women's health needs [3][5] - The program aims to enhance health awareness from individual to societal levels, promoting the core idea of "soothing the liver and relieving stress" [3][5] Group 2 - The collaboration with Meituan to release the "Women's Health White Paper" is a significant initiative in response to the "Healthy China" strategy, aiming to provide more precise health services through data insights and resource integration [5] - The event featured a health consultation area where experienced traditional Chinese medicine practitioners offered personalized health solutions for issues like "liver stagnation and qi deficiency" [7] - Beijing Tongrentang's mission is to make traditional Chinese medicine accessible to everyone, ensuring that every working woman can thrive with a balanced approach to health [7]

Group 1 - The second "Jiawei Xiaoyao Wan - Pharmacy Speaker" event, sponsored by Tongrentang Technology Development Co., Ltd., will start on May 8 and aims to enhance the professional skills of pharmacy staff over a five-month competition [1][3] - The event focuses on empowering pharmacy talent development and improving service quality, aligning with the growing consumer health demands in the domestic market [3][5] - The competition will include various stages such as online preliminaries, online rematch, semifinals, and finals, with opportunities for participants to win cash prizes and gifts [7] Group 2 - The event emphasizes "professional enhancement" and "customer attraction," using Tongrentang's flagship product, Jiawei Xiaoyao Wan, to help pharmacy staff understand product characteristics and market trends [5][3] - Participants can win up to 5,000 yuan in cash rewards and additional prizes for outstanding performance, which can also help drive traffic to their stores [7][5] - The competition format includes PK mode, group challenges, practical exercises, and professional skill contests to comprehensively improve pharmacy operations [5][7]

Core Insights - In Q1 2025, Tongrentang Technology Company focused on market demand, enhancing product variety and channel development to stimulate marketing momentum [1] Group 1: Product Strategy - The company emphasized "focusing" on major products, directing promotional resources towards key varieties such as Yao Medicine 300 Years, Ejiao, and children's medicine, creating a clear product structure [1] - Core products like Xihuang Pill, Jingzhi Niuhuang Jiedu Pian, and Liuwuwei Dihuang Wan series have optimized pricing systems and operational strategies, achieving coverage in over 30 provinces [9] Group 2: Marketing Initiatives - The "Flag Planting Action" marketing campaign covered 10 key provinces, conducting 206 events and nearly 1500 terminal promotion activities, successfully enhancing product shelf presence and awareness [9] - The company targeted younger audiences with innovative marketing strategies, such as the "Beijing Tongrentang Super Good Pill" campaign during the JD Super Brand Day, appealing to their health-conscious yet skeptical mindset [11] Group 3: Community Engagement - The company engaged in community education about product knowledge, leveraging events like the Winter Olympics to promote health trends, particularly in Harbin [11][14] - Creative marketing slogans and campaigns, such as the AI-themed short films, resonated with younger demographics, making products like Jingzhi Niuhuang Jiedu Pian and Ejiao popular during the spring health season [12][14]